A Phase 2 interventional study of Etrasimod 1 mg and Etrasimod 2 mg in Atopic Dermatitis, sponsored by Arena Pharmaceuticals. Completed at 38 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-11-04.
Sponsored by Arena Pharmaceuticals (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Dermatitis, Atopic by Pfizer — 11 open to participants now, 13 under way, 4 of them phase 3. Dermatitis, Atopic · Pfizer.
Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 22nd largest by enrollment of the 47 interventional ones that give a count, is one of 8 that started in 2019, is one of 13 in phase 2, and was the 28th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →11 of the 58 studies in Dermatitis, Atopic by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
Pfizer · Sites in United States, Canada, Japan
Ages 12+
Pfizer · Sites in United States
Ages 12+
Pfizer · Sites in United States, China, Hungary and 4 more countries
Ages 2–11
Pfizer · Sites in United States, Bulgaria, Canada and 6 more countries
Ages 18–64
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 15 · Phase 3 18 · Phase 4 2
First in 2009; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 121 across the 47 interventional studies, 150 across the 9 observational. Of the 43 that completed or were terminated, 34 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Arena Pharmaceuticals, one of the names counted as Pfizer. Under that name alone:
Arena Pharmaceuticals is the lead sponsor of 17 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
4 of the studies in Dermatitis, Atopic by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06899204PfizerReal World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies. | 2027-02-15 |
| NCT06564389PfizerFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients | 2027-06-02 |
| NCT07887867PfizerA Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other Therapies | 2027-10-01 |
| NCT05391061PfizerA Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis | 2027-11-22 |
Add all 4 to your calendar (.ics) → With an account.
Among the 58 studies in Dermatitis, Atopic by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderate-to-severe atopic dermatitis (AD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Etrasimod 1 mg
Drug: Etrasimod 2 mg
Drug: Etrasimod matching placebo
Drug: Etrasimod 2 mg
Etrasimod 1 mg tablet taken by mouth, once daily
Also known as: APD334
Etrasimod 2 mg tablet taken by mouth, once daily.
Also known as: APD334
Etrasimod matching placebo tablet by mouth, once daily.
Double-blind Treatment Period: Percent Change in Eczema Area and Severity Index (EASI) Score
EASI evaluates severity of participant's AD based on severity of AD clinical signs and percent (%) of body surface area (BSA) affected. EASI is a composite scoring assessment of the affected area in 4 specific disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification), which was each assessed on a scale of "0" (absent) through "3" (severe). The EASI Area Score is documented for 4 regions of the body. Region 1: head and neck; Region 2: trunk (including genital area); Region 3: upper limbs; and Region 4: lower limbs (including buttocks), with the area of AD involvement assessed as a percentage by body area and converted to a score of 0 to 6. Total EASI score ranged from 0 to 72; higher score indicated greater severity of AD. Baseline is defined as Day 1 pre-randomization assessments.
Time frame: Baseline (Day 1) and Week 12
Double-blind Treatment Period: Percentage of Participants Achieving EASI-75
EASI-75 is defined as a 75% reduction or greater in EASI score from Baseline to Week 12. Baseline is defined as Day 1 pre-randomization assessments.
Time frame: Baseline (Day 1) and Week 12
Double-blind Treatment Period: Percentage of Participants Achieving a Validated Investigator Global Assessment (vIGA) 0 or 1 Score and a Reduction From Baseline of >= 2 Points
The vIGA scale for AD is a 5-point scale to measure disease severity. The vIGA score was selected using descriptors that best described the overall appearance of skin lesions at a given time point using the following scoring: 0 = clear (no inflammatory signs of AD); 1 = almost clear (barely perceptible erythema and papulation); 2 = mild (slight but definite erythema and papulation); 3 = moderate (clearly perceptible erythema and papulation); and 4 = severe (marked erythema and papulation); Higher score indicated greater severity. Baseline is defined as Day 1 pre-randomization assessments.
Time frame: Baseline (Day 1) and Week 12
Double-blind Treatment Period: Percent Change in Weekly Peak Pruritus Numerical Rating Scale (NRS) From an Itch Daily Diary
Pruritus NRS is an assessment tool that was used to report the intensity of a participant's pruritus (itch). The scale for the pruritus NRS ranged from 0 to 10 with 0 being "no itch" and 10 being "the worst itch imaginable; higher scores indicated greater severity. Baseline is defined as Day 1 pre-randomization assessments.
Time frame: Baseline (Day 1) and Week 12
Double-blind Treatment Period: Percentage of Participants With Improvement (Reduction) in Peak Pruritus NRS Greater Than or Equal to (>=)3 From an Itch Daily Diary
Pruritus NRS is an assessment tool that was used to report the intensity of a participant's pruritus (itch). The scale for the pruritus NRS ranged from 0 to 10 with 0 being "no itch" and 10 being "the worst itch imaginable; higher scores indicated greater severity. Percentage of participants with improvement (reduction) in peak pruritus NRS \>=3 from an itch daily diary is presented. Baseline is defined as Day 1 pre-randomization assessments.
Time frame: Baseline (Day 1) and Week 12
Double-blind Treatment Period: Percentage of Participants Achieving EASI-50
EASI-50 is defined as a 50% reduction or greater of EASI from Baseline to Week 12. Percentage of participants achieving EASI-50 is presented. Baseline is defined as Day 1 pre-randomization assessments.
Time frame: Baseline (Day 1) and Week 12
Double-blind Treatment Period: Percentage of Participants Achieving EASI-90
EASI-90 is defined as as a 90% reduction or greater of EASI from Baseline to Week 12. Percentage of participants achieving EASI-90 is presented Baseline is defined as Day 1 pre-randomization assessments.
Time frame: Baseline (Day 1) and Week 12
Double-blind Treatment Period: Percent Change in Percent Body Surface Area (BSA)
BSA affected by AD were assessed for each section of the body. The possible highest score for each region was: head and neck (9%), anterior trunk (18%), back (18%), upper limbs (18%), lower limbs (36%), and genitals (1%) and were reported as a percentage of all major body sections combined; higher % BSA indicated greater severity. Baseline is defined as Day 1 pre-randomization assessments
Time frame: Baseline (Day 1) and Week 12
Open-label Extension (OLE) Period: Percent Change in EASI
EASI evaluates severity of participant's AD based on severity of AD clinical signs and percent (%) of body surface area (BSA) affected. EASI is a composite scoring assessment of the affected area in 4 specific disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification), which was each assessed on a scale of "0" (absent) through "3" (severe). The EASI Area Score is documented for 4 regions of the body. Region 1: head and neck; Region 2: trunk (including genital area); Region 3: upper limbs; and Region 4: lower limbs (including buttocks), with the area of AD involvement assessed as a percentage by body area and converted to a score of 0 to 6. Total EASI score ranged from 0 to 72; higher score indicated greater severity of AD. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.
Time frame: Baseline (Week 16) and Week 68
OLE Period: Number of Participants Achieving a EASI-75 Score
EASI evaluates severity of participant's AD based on severity of AD clinical signs and percent (%) of body surface area (BSA) affected. EASI is a composite scoring assessment of the affected area in 4 specific disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification), which was each assessed on a scale of "0" (absent) through "3" (severe). The EASI Area Score is documented for 4 regions of the body. Region 1: head and neck; Region 2: trunk (including genital area); Region 3: upper limbs; and Region 4: lower limbs (including buttocks), with the area of AD involvement assessed as a percentage by body area and converted to a score of 0 to 6. Total EASI score ranged from 0 to 72; higher score indicated greater severity of AD. EASI-75 is defined as a \>=75% reduction or greater of EASI from Baseline.
Time frame: Baseline (Week 16) and Week 68
OLE Period: Number of Participants Achieving a Validated Investigator Global Assessment (vIGA) 0 or 1 Score and a Reduction From Baseline of ≥ 2 Points
The vIGA scale for AD is a 5-point scale to measure disease severity. The vIGA score was selected using descriptors that best described the overall appearance of skin lesions at a given time point using the following scoring: 0 = clear (no inflammatory signs of AD); 1 = almost clear (barely perceptible erythema and papulation); 2 = mild (slight but definite erythema and papulation); 3 = moderate (clearly perceptible erythema and papulation); and 4 = severe (marked erythema and papulation); Higher score indicated greater severity.
Time frame: Baseline (Week 16) and Week 68
OLE Period: Percent Change in SCORing Atopic Dermatitis (SCORAD) Total Score
The SCORAD is a validated measure of the extent and severity of AD using 3 components: A = extent or affected BSA, B = severity and C = subjective symptoms. The extent of AD was assessed as percentage of each defined body area and reported as the sum of all areas, with a maximum score of 100%. The severity of 6 specific symptoms was assessed using the following scale: none (0), mild (1), moderate (2), or severe (3) (for a maximum of 18 total points, assigned as "B" in the overall SCORAD calculation). Subjective assessment of itch and sleeplessness was recorded for each symptom by the participant or relative on a Visual Analogue Scale, where 0 is no itch (or sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), with a maximum possible score of 20. This parameter is assigned as "C" in the overall SCORAD calculation. The total SCORAD ranged from 0 (no disease) to 103 (severe disease); higher score indicated more severe AD.
Time frame: Baseline (Week 16) and Week 68
OLE Period: Percent Change in Percent BSA
BSA affected by AD were assessed for each section of the body. The possible highest score for each region was: head and neck (9%), anterior trunk (18%), back (18%), upper limbs (18%), lower limbs (36%), and genitals (1%) and were reported as a percentage of all major body sections combined; higher % BSA indicated greater severity. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.
Time frame: Baseline (Week 16) and Week 68
OLE Period: Percent Change in Weekly Peak Pruritus NRS From an Itch Daily Diary
Pruritus NRS is an assessment tool that was used to report the intensity of a participant's pruritus (itch). The scale for the pruritus NRS ranged from 0 to 10 with 0 being "no itch" and 10 being "the worst itch imaginable; higher scores indicated greater severity. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.
Time frame: Baseline (Week 16) and Week 28
OLE Period: Change in Patient-Oriented Eczema Measure (POEM)
The POEM is a participant-derived validated tool used for monitoring atopic eczema severity. The POEM consisted of 7 questions asking participants to rank how many days over the past 7 days they had experienced specific AD-related symptoms. Each of the 7 questions carried equal weight and was scored from 0 to 4 as follows: No days = 0; 1-2 days = 1; 3-4 days = 2; 5-6 days = 3; Every day = 4. The scores from the 7 questions were added up to give an overall POEM score as: 0-2 = 'clear/almost clear', 3-7 = 'mild', 8-16 = 'moderate', 17-24 = 'severe', and 25-28 = 'very severe atopic eczema'; higher scores indicated worse atopic eczema severity. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.
Time frame: Baseline (Week 16) and Week 68
OLE Period: Change in Dermatology Life Quality Index (DLQI)
The DLQI is a validated 10-item questionnaire designed to measure the impact of skin disease on the Quality of Life (QoL). DLQI is a response to 10 items, which assessed QoL over the past week. For each item, the scale was rated as follows: 0 = "not at all"; 1 = "a little"; 2 = "a lot"; 3 = "very much," with an overall scoring system of 0 to 30; higher scores indicated a poor QoL. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.
Time frame: Baseline (Week 16) and Week 68
OLE Period: Change in Patient Global Assessment (PGA) of Disease
PGA is an assessment tool that was used by participant to rate the disease and disease severity. Participants rated their overall well-being based on a 5-point Likert scale from poor to excellent. Response choices were: 1- 'Poor', 2- 'Fair', 3- 'Good', 4- 'Very Good,' or 5- 'Excellent'; higher scores indicated better well-being. For the 5-point Likert scale, a positive change from baseline indicates an improvement. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.
Time frame: Baseline (Week 16) and Week 68
This was a 2-treatment period study (12-Week Double-Blind Treatment Period and 52-Week Open-label extension \[OLE\] Period), to evaluate the safety and efficacy of etrasimod monotherapy compared with placebo in participants with moderate-to-severe atopic dermatitis (AD), whose disease was not adequately controlled with topical therapies.
| Milestone | Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) | Double-blind Treatment Period: Etrasimod 2 mg | Double-blind Treatment Period: Placebo | OLE Period: Etrasimod 2 mg |
|---|---|---|---|---|
| Started | 47 | 47 | 46 | 0 |
| Completed | 34 | 36 | 37 | 0 |
| Not completed | 13 | 11 | 9 | 0 |
| Withdrew: Adverse event | 2 | 5 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 3 | 2 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 1 | 6 | 0 |
| Withdrew: Protocol deviation | 1 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 1 | 0 |
| Milestone | Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) | Double-blind Treatment Period: Etrasimod 2 mg | Double-blind Treatment Period: Placebo | OLE Period: Etrasimod 2 mg |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 95 |
| Completed | 0 | 0 | 0 | 68 |
| Not completed | 0 | 0 | 0 | 27 |
| Withdrew: Adverse event | 0 | 0 | 0 | 5 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 10 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 9 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 2 |
EASI evaluates severity of participant's AD based on severity of AD clinical signs and percent (%) of body surface area (BSA) affected. EASI is a composite scoring assessment of the affected area in 4 specific disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification), which was each assessed on a scale of "0" (absent) through "3" (severe). The EASI Area Score is documented for 4 regions of the body. Region 1: head and neck; Region 2: trunk (including genital area); Region 3: upper limbs; and Region 4: lower limbs (including buttocks), with the area of AD involvement assessed as a percentage by body area and converted to a score of 0 to 6. Total EASI score ranged from 0 to 72; higher score indicated greater severity of AD. Baseline is defined as Day 1 pre-randomization assessments.
| Percent change | Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) | Double-blind Treatment Period: Etrasimod 2 mg | Double-blind Treatment Period: Placebo |
|---|---|---|---|
| Double-blind Treatment Period: Percent Change in Eczema Area and Severity Index (EASI) Score | -58.68 ± 7.735 | -57.18 ± 7.800 | -48.41 ± 8.378 |
EASI-75 is defined as a 75% reduction or greater in EASI score from Baseline to Week 12. Baseline is defined as Day 1 pre-randomization assessments.
| Percentage of participants | Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) | Double-blind Treatment Period: Etrasimod 2 mg | Double-blind Treatment Period: Placebo |
|---|---|---|---|
| Double-blind Treatment Period: Percentage of Participants Achieving EASI-75 | 27.7 (15.62 to 42.64) | 38.3 (24.51 to 53.62) | 26.1 (14.27 to 41.13) |
The vIGA scale for AD is a 5-point scale to measure disease severity. The vIGA score was selected using descriptors that best described the overall appearance of skin lesions at a given time point using the following scoring: 0 = clear (no inflammatory signs of AD); 1 = almost clear (barely perceptible erythema and papulation); 2 = mild (slight but definite erythema and papulation); 3 = moderate (clearly perceptible erythema and papulation); and 4 = severe (marked erythema and papulation); Higher score indicated greater severity. Baseline is defined as Day 1 pre-randomization assessments.
| Percentage of participants | Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) | Double-blind Treatment Period: Etrasimod 2 mg | Double-blind Treatment Period: Placebo |
|---|---|---|---|
| Double-blind Treatment Period: Percentage of Participants Achieving a Validated Investigator Global Assessment (vIGA) 0 or 1 Score and a Reduction From Baseline of >= 2 Points | 14.9 (6.20 to 28.31) | 29.8 (17.34 to 44.89) | 13.0 (4.94 to 26.26) |
Pruritus NRS is an assessment tool that was used to report the intensity of a participant's pruritus (itch). The scale for the pruritus NRS ranged from 0 to 10 with 0 being "no itch" and 10 being "the worst itch imaginable; higher scores indicated greater severity. Baseline is defined as Day 1 pre-randomization assessments.
| Percent change | Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) | Double-blind Treatment Period: Etrasimod 2 mg | Double-blind Treatment Period: Placebo |
|---|---|---|---|
| Double-blind Treatment Period: Percent Change in Weekly Peak Pruritus Numerical Rating Scale (NRS) From an Itch Daily Diary | -38.401 ± 8.236 | -35.044 ± 7.910 | -24.374 ± 8.492 |
Pruritus NRS is an assessment tool that was used to report the intensity of a participant's pruritus (itch). The scale for the pruritus NRS ranged from 0 to 10 with 0 being "no itch" and 10 being "the worst itch imaginable; higher scores indicated greater severity. Percentage of participants with improvement (reduction) in peak pruritus NRS \>=3 from an itch daily diary is presented. Baseline is defined as Day 1 pre-randomization assessments.
| Percentage of participants | Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) | Double-blind Treatment Period: Etrasimod 2 mg | Double-blind Treatment Period: Placebo |
|---|---|---|---|
| Double-blind Treatment Period: Percentage of Participants With Improvement (Reduction) in Peak Pruritus NRS Greater Than or Equal to (>=)3 From an Itch Daily Diary | 45.0 (29.26 to 61.51) | 45.0 (29.26 to 61.51) | 41.0 (25.57 to 57.90) |
EASI-50 is defined as a 50% reduction or greater of EASI from Baseline to Week 12. Percentage of participants achieving EASI-50 is presented. Baseline is defined as Day 1 pre-randomization assessments.
| Percentage of participants | Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) | Double-blind Treatment Period: Etrasimod 2 mg | Double-blind Treatment Period: Placebo |
|---|---|---|---|
| Double-blind Treatment Period: Percentage of Participants Achieving EASI-50 | 61.7 (46.38 to 75.49) | 66.0 (50.69 to 79.14) | 52.2 (36.95 to 67.11) |
EASI-90 is defined as as a 90% reduction or greater of EASI from Baseline to Week 12. Percentage of participants achieving EASI-90 is presented Baseline is defined as Day 1 pre-randomization assessments.
| Percentage of participants | Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) | Double-blind Treatment Period: Etrasimod 2 mg | Double-blind Treatment Period: Placebo |
|---|---|---|---|
| Double-blind Treatment Period: Percentage of Participants Achieving EASI-90 | 19.1 (9.15 to 33.26) | 14.9 (6.20 to 28.31) | 10.9 (3.62 to 23.57) |
BSA affected by AD were assessed for each section of the body. The possible highest score for each region was: head and neck (9%), anterior trunk (18%), back (18%), upper limbs (18%), lower limbs (36%), and genitals (1%) and were reported as a percentage of all major body sections combined; higher % BSA indicated greater severity. Baseline is defined as Day 1 pre-randomization assessments
| Percent change | Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) | Double-blind Treatment Period: Etrasimod 2 mg | Double-blind Treatment Period: Placebo |
|---|---|---|---|
| Double-blind Treatment Period: Percent Change in Percent Body Surface Area (BSA) | -34.725 ± 7.047 | -45.153 ± 6.860 | -31.913 ± 7.012 |
EASI evaluates severity of participant's AD based on severity of AD clinical signs and percent (%) of body surface area (BSA) affected. EASI is a composite scoring assessment of the affected area in 4 specific disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification), which was each assessed on a scale of "0" (absent) through "3" (severe). The EASI Area Score is documented for 4 regions of the body. Region 1: head and neck; Region 2: trunk (including genital area); Region 3: upper limbs; and Region 4: lower limbs (including buttocks), with the area of AD involvement assessed as a percentage by body area and converted to a score of 0 to 6. Total EASI score ranged from 0 to 72; higher score indicated greater severity of AD. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.
| Percent change | OLE Period: Etrasimod 2 mg |
|---|---|
| Open-label Extension (OLE) Period: Percent Change in EASI | -45.39 ± 258.796 |
EASI evaluates severity of participant's AD based on severity of AD clinical signs and percent (%) of body surface area (BSA) affected. EASI is a composite scoring assessment of the affected area in 4 specific disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification), which was each assessed on a scale of "0" (absent) through "3" (severe). The EASI Area Score is documented for 4 regions of the body. Region 1: head and neck; Region 2: trunk (including genital area); Region 3: upper limbs; and Region 4: lower limbs (including buttocks), with the area of AD involvement assessed as a percentage by body area and converted to a score of 0 to 6. Total EASI score ranged from 0 to 72; higher score indicated greater severity of AD. EASI-75 is defined as a \>=75% reduction or greater of EASI from Baseline.
| Participants | OLE Period: Etrasimod 2 mg |
|---|---|
| OLE Period: Number of Participants Achieving a EASI-75 Score | 65 |
The vIGA scale for AD is a 5-point scale to measure disease severity. The vIGA score was selected using descriptors that best described the overall appearance of skin lesions at a given time point using the following scoring: 0 = clear (no inflammatory signs of AD); 1 = almost clear (barely perceptible erythema and papulation); 2 = mild (slight but definite erythema and papulation); 3 = moderate (clearly perceptible erythema and papulation); and 4 = severe (marked erythema and papulation); Higher score indicated greater severity.
| Participants | OLE Period: Etrasimod 2 mg |
|---|---|
| OLE Period: Number of Participants Achieving a Validated Investigator Global Assessment (vIGA) 0 or 1 Score and a Reduction From Baseline of ≥ 2 Points | 31 |
The SCORAD is a validated measure of the extent and severity of AD using 3 components: A = extent or affected BSA, B = severity and C = subjective symptoms. The extent of AD was assessed as percentage of each defined body area and reported as the sum of all areas, with a maximum score of 100%. The severity of 6 specific symptoms was assessed using the following scale: none (0), mild (1), moderate (2), or severe (3) (for a maximum of 18 total points, assigned as "B" in the overall SCORAD calculation). Subjective assessment of itch and sleeplessness was recorded for each symptom by the participant or relative on a Visual Analogue Scale, where 0 is no itch (or sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), with a maximum possible score of 20. This parameter is assigned as "C" in the overall SCORAD calculation. The total SCORAD ranged from 0 (no disease) to 103 (severe disease); higher score indicated more severe AD.
| Percent change | OLE Period: Etrasimod 2 mg |
|---|---|
| OLE Period: Percent Change in SCORing Atopic Dermatitis (SCORAD) Total Score | -64.27 ± 69.273 |
BSA affected by AD were assessed for each section of the body. The possible highest score for each region was: head and neck (9%), anterior trunk (18%), back (18%), upper limbs (18%), lower limbs (36%), and genitals (1%) and were reported as a percentage of all major body sections combined; higher % BSA indicated greater severity. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.
| Percent change | OLE Period: Etrasimod 2 mg |
|---|---|
| OLE Period: Percent Change in Percent BSA | -68.47 ± 52.083 |
Pruritus NRS is an assessment tool that was used to report the intensity of a participant's pruritus (itch). The scale for the pruritus NRS ranged from 0 to 10 with 0 being "no itch" and 10 being "the worst itch imaginable; higher scores indicated greater severity. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.
| Percent change | OLE Period: Etrasimod 2 mg |
|---|---|
| OLE Period: Percent Change in Weekly Peak Pruritus NRS From an Itch Daily Diary | -36.87 ± 45.219 |
The POEM is a participant-derived validated tool used for monitoring atopic eczema severity. The POEM consisted of 7 questions asking participants to rank how many days over the past 7 days they had experienced specific AD-related symptoms. Each of the 7 questions carried equal weight and was scored from 0 to 4 as follows: No days = 0; 1-2 days = 1; 3-4 days = 2; 5-6 days = 3; Every day = 4. The scores from the 7 questions were added up to give an overall POEM score as: 0-2 = 'clear/almost clear', 3-7 = 'mild', 8-16 = 'moderate', 17-24 = 'severe', and 25-28 = 'very severe atopic eczema'; higher scores indicated worse atopic eczema severity. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.
| Scores on a scale | OLE Period: Etrasimod 2 mg |
|---|---|
| OLE Period: Change in Patient-Oriented Eczema Measure (POEM) | -6.3 ± 6.50 |
The DLQI is a validated 10-item questionnaire designed to measure the impact of skin disease on the Quality of Life (QoL). DLQI is a response to 10 items, which assessed QoL over the past week. For each item, the scale was rated as follows: 0 = "not at all"; 1 = "a little"; 2 = "a lot"; 3 = "very much," with an overall scoring system of 0 to 30; higher scores indicated a poor QoL. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.
| Scores on a scale | OLE Period: Etrasimod 2 mg |
|---|---|
| OLE Period: Change in Dermatology Life Quality Index (DLQI) | -5.4 ± 6.03 |
PGA is an assessment tool that was used by participant to rate the disease and disease severity. Participants rated their overall well-being based on a 5-point Likert scale from poor to excellent. Response choices were: 1- 'Poor', 2- 'Fair', 3- 'Good', 4- 'Very Good,' or 5- 'Excellent'; higher scores indicated better well-being. For the 5-point Likert scale, a positive change from baseline indicates an improvement. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.
| Scores on a scale | OLE Period: Etrasimod 2 mg |
|---|---|
| OLE Period: Change in Patient Global Assessment (PGA) of Disease | 1.23 ± 1.209 |
Collected over All-cause mortality, TEAEs and SAEs were collected for Double-blind Treatment period (12-Week) and for OLE Period (52-Week).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) | 0/47 (0%) | 0/47 (0%) | 19/47 (40.4%) |
| Double-blind Treatment Period: Etrasimod 2 mg | 0/47 (0%) | 0/47 (0%) | 31/47 (66%) |
| Double-blind Treatment Period: Placebo | 0/46 (0%) | 0/46 (0%) | 22/46 (47.8%) |
| OLE Period: Etrasimod 2 mg | 0/95 (0%) | 3/95 (3.2%) | 53/95 (55.8%) |
| Event | Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) | Double-blind Treatment Period: Etrasimod 2 mg | Double-blind Treatment Period: Placebo | OLE Period: Etrasimod 2 mg |
|---|---|---|---|---|
| Extradural abscessInfections and infestations | 0/47 | 0/47 | 0/46 | 1/95 |
| Staphylococcal bacteraemiaInfections and infestations | 0/47 | 0/47 | 0/46 | 1/95 |
| Tooth abscessInfections and infestations | 0/47 | 0/47 | 0/46 | 1/95 |
| PneumoniaInfections and infestations | 0/47 | 0/47 | 0/46 | 1/95 |
| SepsisInfections and infestations | 0/47 | 0/47 | 0/46 | 1/95 |
| Arthropod biteInjury, poisoning and procedural complications | 0/47 | 0/47 | 0/46 | 1/95 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 0/47 | 0/47 | 0/46 | 1/95 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/47 | 0/47 | 0/46 | 1/95 |
| Event | Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) | Double-blind Treatment Period: Etrasimod 2 mg | Double-blind Treatment Period: Placebo | OLE Period: Etrasimod 2 mg |
|---|---|---|---|---|
| Lymphocyte count decreasedInvestigations | 1/47 | 7/47 | 0/46 | 7/95 |
| HeadacheNervous system disorders | 1/47 | 0/47 | 4/46 | 5/95 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/47 | 2/47 | 4/46 | 5/95 |
| Urinary tract infectionInfections and infestations | 0/47 | 3/47 | 3/46 | 3/95 |
| ConstipationGastrointestinal disorders | 0/47 | 3/47 | 0/46 | 1/95 |
| NauseaGastrointestinal disorders | 1/47 | 3/47 | 2/46 | 4/95 |
| Back painMusculoskeletal and connective tissue disorders | 0/47 | 3/47 | 1/46 | 2/95 |
| DizzinessNervous system disorders | 2/47 | 3/47 | 1/46 | 4/95 |
| SARS-CoV-2 test positiveInvestigations | 0/47 | 0/47 | 0/46 | 5/95 |
| Herpes zosterInfections and infestations | 0/47 | 0/47 | 2/46 | 0/95 |
Full Analysis Set (FAS) included all randomized participants, irrespective of whether they received any study intervention.
| Age, Continuous(Years) | Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) | Double-blind Treatment Period: Etrasimod 2 mg | Double-blind Treatment Period: Placebo | Total |
|---|---|---|---|---|
| Mean | 41.7 ± 13.32 | 41.8 ± 14.83 | 44.1 ± 16.16 | 42.5 ± 14.74 |
| Sex: Female, Male(Participants) | Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) | Double-blind Treatment Period: Etrasimod 2 mg | Double-blind Treatment Period: Placebo | Total |
|---|---|---|---|---|
| Female | 30 | 28 | 27 | 85 |
| Male | 17 | 19 | 19 | 55 |
| Race/Ethnicity, Customized(Participants) | Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) | Double-blind Treatment Period: Etrasimod 2 mg | Double-blind Treatment Period: Placebo | Total |
|---|---|---|---|---|
| White | 27 | 26 | 31 | 84 |
| Asian | 2 | 3 | 2 | 7 |
| Black or African American | 15 | 18 | 11 | 44 |
| American Indian or Alaska Native | 2 | 0 | 1 | 3 |
| Native Hawaiian or other Pacific Islander | 1 | 0 | 0 | 1 |
| Other | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2019 to primary completion in Sep 2020, 11 months.
Results were first posted in Nov 2022, 2 years 1 month after primary completion. A results delay was requested in Sep 2021.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 11 months is below that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etrasimod